Tinlarebant (LBS-008) is an orally active non-retinoid RBP4 (retinol-binding protein 4) antagonist. Tinlarebant can be used for the research of the Stargardt disease [1].
In Vitro, Retinol-binding protein 4 (RBP4) is a serum protein that transports Vitamin A. RBP4 is correlated with numerous diseases and metabolic syndromes, including insulin resistance in type 2 diabetes, cardiovascular diseases, obesity, and macular degeneration[1].
References:
[1]. Kim N, et al. Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development [published online ahead of print, 2021 Sep 15]. Eur J Med Chem. 2021;226:113856.
In Vitro, Retinol-binding protein 4 (RBP4) is a serum protein that transports Vitamin A. RBP4 is correlated with numerous diseases and metabolic syndromes, including insulin resistance in type 2 diabetes, cardiovascular diseases, obesity, and macular degeneration[1].
References:
[1]. Kim N, et al. Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development [published online ahead of print, 2021 Sep 15]. Eur J Med Chem. 2021;226:113856.